Literature DB >> 1831795

Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

T R Kozel1, M A Wilson, J W Murphy.   

Abstract

The capsule of Cryptococcus neoformans is a powerful activator of the alternative complement pathway. This study examined the manner in which the cryptococcal capsule influences initiation of and early events in complement activation by C. neoformans. These studies examined the effects of the classical and alternative pathways on the kinetics and early sites for deposition of C3 fragments on encapsulated cryptococci, nonencapsulated cryptococci, and zymosan. The results showed that nonencapsulated cryptococci and zymosan are qualitatively and quantitatively similar in the manner in which they initiate complement activation. Both utilize the classical and alternative pathways. Initiation via the classical pathway occurs suddenly and simultaneously at sites distributed over the entire cell surface. Initiation of the alternative pathway by zymosan and nonencapsulated cryptococci is characterized by a lag of 6 to 8 min before appreciable amounts of C3 accumulate on the cells. Alternative pathway initiation by zymosan and nonencapsulated cryptococci occurs at a limited number of focal initiation sites that expand with alternative pathway amplification to cover the cell surface. Presence of the cryptococcal capsule blocks classical pathway initiation, which would normally occur at the cryptococcal cell wall, and produces an initiation that is dependent solely on the alternative pathway. Initiation of the alternative pathway by the cryptococcal capsule is characterized by a lag in C3 accumulation and the appearance of a limited number of focal initiation sites which resemble those observed when the alternative pathway is activated by zymosan and nonencapsulated cryptococci.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831795      PMCID: PMC258140          DOI: 10.1128/IAI.59.9.3101-3110.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

Review 2.  Phagocytosis of particulate activators of the alternative complement pathway: effects of fibronectin.

Authors:  J K Czop
Journal:  Adv Immunol       Date:  1986       Impact factor: 3.543

Review 3.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.

Authors:  T R Kozel; G S Pfrommer; A S Guerlain; B A Highison; G J Highison
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

5.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Species specificity of recognition by the alternative pathway of complement.

Authors:  R D Horstmann; M K Pangburn; H J Müller-Eberhard
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

7.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

8.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

Review 9.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

10.  The use of lead citrate at high pH as an electron-opaque stain in electron microscopy.

Authors:  E S REYNOLDS
Journal:  J Cell Biol       Date:  1963-04       Impact factor: 10.539

View more
  45 in total

1.  In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.

Authors:  K Truelsen; T Young; T R Kozel
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Structural transitions of complement component C3 and its activation products.

Authors:  Noritaka Nishida; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

4.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

5.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

6.  Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.

Authors:  R Blackstock; J W Murphy
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

7.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

8.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.

Authors:  E Blasi; R Mazzolla; R Barluzzi; P Mosci; F Bistoni
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.